Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report
Crossref DOI link: https://doi.org/10.1186/s12902-016-0148-0
Published Online: 2016-11-24
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Takeno, Ayumu
Yamamoto, Masahiro
Notsu, Masakazu
Sugimoto, Toshitsugu
License valid from 2016-11-24